Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

Arnulf Stenzl, MD, medical director of the Department of Urology at the University of Tübingen in Germany, discusses future research efforts with enzalutamide (Xtandi) in prostate cancer.

Combination therapy is an exciting area of research in the prostate cancer paradigm, says Stenzl.

Moreover, the positive efficacy and safety data observed with enzalutamide may provide an opportunity for the agent to be combined with immunotherapy, Stenzl adds.

For example, checkpoint inhibitors may be an effective partner for the potent antiandrogen agent, Stenzl says.

Additionally, it is worth considering whether these combinations can be given perioperatively or concurrently with local therapy, concludes Stenzl.